Scientists are exploring how GLP-1 drugs like Ozempic may not only be a metabolism breakthrough but could also reshape some patients' brains. Researchers at the University of Colorado Anschutz have found that the drugs increased brain connectivity in some patients and may rewire brains beyond quieting appetites, according to the Washington Post.
While scientists stressed there are still many unknowns with GLP-1 drugs and research is limited, some patients taking the medication have reported positive impacts aside from decreased hunger or food cravings. The drug has reportedly made some patients less likely to drink alcohol or act compulsively, and early studies are being carried out on how the medication could one day be used as a possible treatment for addiction. GLP-1s have also improved attention spans in some cases.
Previous studies have suggested that the drugs may slow the loss of volume in parts of the brain required for planning, memory, emotion and sensory integration. Scientists are also studying whether GLP-1s could delay or prevent diseases like Alzheimer's. However, a recent clinical trial did not show any overall impact on Parkinson's, and a large late-phase trial for Alzheimer's failed to show that the medication significantly slowed cognitive and functional decline.
The findings at the University of Colorado Anschutz were made as researchers studied young women taking GLP-1 medications to treat a common hormonal condition, PCOS (now renamed PMOS). Within a few months of use, patients' brain connections in the salience network, which helps target attention, had multiplied, said lead researcher Allison Shapiro. “We didn’t expect to see this effect, and we really don’t know what it means,” she told the Post.
While many people have reported positive impacts, some users have reported brain fog, while others say they experience less pleasure and are less motivated. The scientists cautioned that this research is still in the early stages, and they have yet to determine what these changes mean long term. Researchers have also questioned how these drugs might impact children's developing brains. Shapiro hopes to continue studying the potential impacts on children and whether neural changes will be lasting.
Grace Hamilton, a study participant who has been on GLP-1s since her early 20s, said she has noticed several impactful changes. The 28-year-old no longer needs antidepressants and has stopped drinking alcohol. “I would probably stand to bet it’s not a coincidence,” she told the Post.
